Source: NEJM FREGAT Trial Key Points Minimally invasive esophagectomy (MIE) was found to have significantly lower complications and side effects compared to open esophagectomy. The 3 years survival rate was also higher among patients undergoing minimal invasive esophagectomy. Open esophagectomy is known to have significant morbidity ranging from 17.9% to 58%, with up to 6% mortality. Therefore, the..
PACIFIC Trial Summary (NEJM 2018): Scott J et al. randomized 713 patients with stage III unresectable nonsmall cell lung cancer (NSCLC) who did not have disease progression after concurrent chemoradiotherapy were randomized to either Durvalumab 10mg/kg body weight twice weekly for 12 months (n=473) or matching placebo (n=236). The primary objective was to assess if..
2018, Apixaban to Prevent Venous Thromboembolism in Patients with Cancer, NEJM The AVERT trial evaluated the use of apixaban for preventing venous thromboemboli such as deep venous thrombosis and pulmonary embolism in patients with cancer who were scheduled to start chemotherapy. These patients were at high risk of VTE based on the Khorana score. The point..
2006, Effect of mammographic screening from age 40 years on breast cancer mortality at 10 years, The Lancet
Full trial results to follow the publication. This abstract format was presented at the WCLC 2018.
2015, Cancer screening in unprovoked venous thromboembolism, NEJM